Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.
Animals
Antineoplastic Agents
/ administration & dosage
Breast Neoplasms
/ blood supply
Drug Delivery Systems
/ methods
Drug Resistance, Neoplasm
/ drug effects
Humans
Inflammation
/ pathology
Nanoparticles
/ chemistry
Neovascularization, Pathologic
/ prevention & control
Tumor Microenvironment
/ drug effects
Breast cancer
Chemotherapy
Drug targeting
Inflammation
Nanoparticle
Tumor microenvironment
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
24
05
2020
accepted:
31
10
2020
revised:
20
09
2020
pubmed:
3
1
2021
medline:
30
3
2021
entrez:
2
1
2021
Statut:
ppublish
Résumé
Tumor cells, inflammatory cells and chemical factors work together to mediate complex signaling networks, which forms inflammatory tumor microenvironment (TME). The development of breast cancer is closely related to the functional activities of TME. This review introduces the origins of cancer-related chronic inflammation and the main constituents of inflammatory microenvironment. Inflammatory microenvironment plays an important role in breast cancer growth, metastasis, drug resistance and angiogenesis through multifactorial mechanisms. It is suggested that inflammatory microenvironment contributes to providing possible mechanisms of drug action and modes of drug transport for anti-cancer treatment. Nano-drug delivery system (NDDS) becomes a popular topic for optimizing the design of tumor targeting drugs. It is seen that with the development of therapeutic approaches, NDDS can be used to achieve drug-targeted delivery well across the biological barriers and into cells, resulting in superior bioavailability, drug dose reduction as well as off-target side effect elimination. This paper focuses on the review of modulation mechanisms of inflammatory microenvironment and combination with nano-targeted therapeutic strategies, providing a comprehensive basis for further research on breast cancer prevention and control.
Identifiants
pubmed: 33386887
doi: 10.1007/s00018-020-03696-4
pii: 10.1007/s00018-020-03696-4
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2105-2129Subventions
Organisme : Natural Science Foundation of Guangdong
ID : 2019A1515011286
Organisme : the Open Project funded by Key laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing
ID : 2019 Open Project-05
Organisme : the National Natural Science Foundation of China
ID : 81973839
Organisme : the Projects of International Cooperation and Exchanges of National Natural Science Foundation of China
ID : 82020108033
Références
Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128(11):2527–2535. https://doi.org/10.1002/ijc.26031
doi: 10.1002/ijc.26031
pubmed: 3075088
pmcid: 3075088
Silva AL, Faria M, Matos P (2020) Inflammatory microenvironment modulation of alternative splicing in cancer: a way to adapt. In: Serpa J (ed) Tumor microenvironment: the main driver of metabolic adaptation. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-030-34025-4_13
doi: 10.1007/978-3-030-34025-4_13
Huang A, Cao S, Tang L (2017) The tumor microenvironment and inflammatory breast cancer. J Cancer 8(10):1884–1891. https://doi.org/10.7150/jca.17595
doi: 10.7150/jca.17595
pubmed: 28819386
pmcid: 5556652
Marmé D (2018) Tumor angiogenesis: a key target for cancer therapy. Oncol Res Treat 41(4):164–164. https://doi.org/10.1159/000488340
doi: 10.1159/000488340
pubmed: 29587285
Brueggemeier RW, Hackett JC, Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26(3):331–345. https://doi.org/10.1210/er.2004-0015
doi: 10.1210/er.2004-0015
pubmed: 15814851
Camacho L, Dasgupta A, Jiralerspong S (2015) Metformin in breast cancer—an evolving mystery. Breast Cancer Res 17(1):88–88. https://doi.org/10.1186/s13058-015-0598-8
doi: 10.1186/s13058-015-0598-8
pubmed: 26111812
pmcid: 4480505
Hua S, de Matos MBC, Metselaar JM, Storm G (2018) Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 9:790–790. https://doi.org/10.3389/fphar.2018.00790
doi: 10.3389/fphar.2018.00790
pubmed: 30065653
pmcid: 6056679
Murata M (2018) Inflammation and cancer. Environ Health Prev Med 23(1):50–50. https://doi.org/10.1186/s12199-018-0740-1
doi: 10.1186/s12199-018-0740-1
pubmed: 30340457
pmcid: 6195709
Qu X, Tang Y, Hua S (2018) Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol 9:563–563. https://doi.org/10.3389/fimmu.2018.00563
doi: 10.3389/fimmu.2018.00563
pubmed: 29662489
pmcid: 5890100
Raposo TP, Beirão BCB, Pang LY, Queiroga FL, Argyle DJ (2015) Inflammation and cancer: till death tears them apart. Vet J 205(2):161–174. https://doi.org/10.1016/j.tvjl.2015.04.015
doi: 10.1016/j.tvjl.2015.04.015
pubmed: 25981934
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Yu T, Di G (2017) Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin J Cancer Res 29(3):237–252. https://doi.org/10.21147/j.issn.1000-9604.2017.03.10
doi: 10.21147/j.issn.1000-9604.2017.03.10
pubmed: 28729775
pmcid: 5497211
Nisticò P, Ciliberto G (2020) Biological mechanisms linked to inflammation in cancer: discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. Int J Biol Markers 35(1_suppl):8–11. https://doi.org/10.1177/1724600820906155
doi: 10.1177/1724600820906155
pubmed: 32079468
Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82(3–4):142–152. https://doi.org/10.1159/000430499
doi: 10.1159/000430499
pubmed: 26330355
Cronkite DA, Strutt TM (2018) The regulation of inflammation by innate and adaptive lymphocytes. J Immunol Res 2018:1467538–1467538. https://doi.org/10.1155/2018/1467538
doi: 10.1155/2018/1467538
pubmed: 29992170
pmcid: 6016164
Comen EA, Bowman RL, Kleppe M (2018) Underlying causes and therapeutic targeting of the inflammatory tumor microenvironment. Front Cell Dev Biol 6:56–56. https://doi.org/10.3389/fcell.2018.00056
doi: 10.3389/fcell.2018.00056
pubmed: 29946544
pmcid: 6005853
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20(3):174–186. https://doi.org/10.1038/s41568-019-0238-1
doi: 10.1038/s41568-019-0238-1
pubmed: 31980749
pmcid: 7046529
Burkholder B, Huang R-Y, Burgess R, Luo S, Jones VS, Zhang W, Lv Z-Q, Gao C-Y, Wang B-L, Zhang Y-M (1845) Huang R-P (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochimica et Biophysica Acta (BBA) Rev Cancer 2:182–201. https://doi.org/10.1016/j.bbcan.2014.01.004
doi: 10.1016/j.bbcan.2014.01.004
Eftekhari R, Esmaeili R, Mirzaei R, Bidad K, de Lima S, Ajami M, Shirzad H, Hadjati J, Majidzadeh-A K (2017) Study of the tumor microenvironment during breast cancer progression. Cancer Cell Int 17:123–123. https://doi.org/10.1186/s12935-017-0492-9
doi: 10.1186/s12935-017-0492-9
pubmed: 29299026
pmcid: 5741925
Munn DH, Sharma MD, Johnson TS (2018) Treg destabilization and reprogramming: implications for cancer immunotherapy. Cancer Res 78(18):5191–5199. https://doi.org/10.1158/0008-5472.CAN-18-1351
doi: 10.1158/0008-5472.CAN-18-1351
pubmed: 30181177
pmcid: 6139039
Salimifard S, Masjedi A, Hojjat-Farsangi M, Ghalamfarsa G, Irandoust M, Azizi G, Mohammadi H, Keramati MR, Jadidi-Niaragh F (2020) Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. Pathol Res Pract 216(5):152915. https://doi.org/10.1016/j.prp.2020.152915
doi: 10.1016/j.prp.2020.152915
pubmed: 32146002
Vetsika E-K, Koukos A, Kotsakis A (2019) Myeloid-Derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer. Cells 8(12):1647. https://doi.org/10.3390/cells8121647
doi: 10.3390/cells8121647
pmcid: 6953061
Feichtinger RG, Lang R (2019) Targeting L-lactate metabolism to overcome resistance to immune therapy of melanoma and other tumor entities. J Oncol 2019:2084195–2084195. https://doi.org/10.1155/2019/2084195
doi: 10.1155/2019/2084195
pubmed: 31781212
pmcid: 6875281
Fernandes JV, Cobucci RNO, Jatobá CAN, de Medeiros Fernandes TAA, de Azevedo JWV, de Araújo JMG (2015) The role of the mediators of inflammation in cancer development. Pathol Oncol Res 21(3):527–534. https://doi.org/10.1007/s12253-015-9913-z
doi: 10.1007/s12253-015-9913-z
pubmed: 25740073
da Cunha BR, Domingos C, Stefanini ACB, Henrique T, Polachini GM, Castelo-Branco P, Tajara EH (2019) Cellular interactions in the tumor microenvironment: the role of secretome. J Cancer 10(19):4574–4587. https://doi.org/10.7150/jca.21780
doi: 10.7150/jca.21780
pubmed: 31528221
pmcid: 6746126
Lins Ferreira V, Borba H, Bonetti A, Leonart L, Pontarolo R (2018) Cytokines and interferons: types and functions. IntechOpen, London. https://doi.org/10.5772/intechopen.74550
doi: 10.5772/intechopen.74550
Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J (2015) The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res 35(1):1–16. https://doi.org/10.1089/jir.2014.0026
doi: 10.1089/jir.2014.0026
pubmed: 25068787
pmcid: 4291218
Nagarsheth N, Wicha MS, Zou W (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17(9):559–572. https://doi.org/10.1038/nri.2017.49
doi: 10.1038/nri.2017.49
pubmed: 28555670
pmcid: 28555670
Chen Y, Tan W, Wang C (2018) Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. Onco Targets Ther 11:3817–3826. https://doi.org/10.2147/OTT.S168317
doi: 10.2147/OTT.S168317
pubmed: 30013362
pmcid: 6038883
Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z (2019) Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 26(1):78–78. https://doi.org/10.1186/s12929-019-0568-z
doi: 10.1186/s12929-019-0568-z
pubmed: 31629410
pmcid: 6800990
Petty AJ, Yang Y (2017) Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy 9(3):289–302. https://doi.org/10.2217/imt-2016-0135
doi: 10.2217/imt-2016-0135
pubmed: 28231720
pmcid: 5619052
Shrihari TG (2017) Dual role of inflammatory mediators in cancer. Ecancermedicalscience 11:721–721. https://doi.org/10.3332/ecancer.2017.721
doi: 10.3332/ecancer.2017.721
pubmed: 28275390
pmcid: 5336391
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284. https://doi.org/10.1101/gad.314617.118
doi: 10.1101/gad.314617.118
pubmed: 30275043
pmcid: 30275043
Williams CB, Yeh ES, Soloff AC (2016) Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer 2:15025. https://doi.org/10.1038/npjbcancer.2015.25
doi: 10.1038/npjbcancer.2015.25
pubmed: 26998515
pmcid: 4794275
Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R (2019) Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol 12(1):86. https://doi.org/10.1186/s13045-019-0770-1
doi: 10.1186/s13045-019-0770-1
pubmed: 31462327
pmcid: 6714445
Liu L, Liu L, Yao HH, Zhu ZQ, Ning ZL, Huang Q (2016) Stromal myofibroblasts are associated with poor prognosis in solid cancers: a meta-analysis of published studies. PLoS ONE 11(7):e0159947–e0159947. https://doi.org/10.1371/journal.pone.0159947
doi: 10.1371/journal.pone.0159947
pubmed: 27459365
pmcid: 4961396
Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL (2019) Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 16(5):282–295. https://doi.org/10.1038/s41575-019-0115-0
doi: 10.1038/s41575-019-0115-0
pubmed: 30778141
Yan Y, Chen X, Wang X, Zhao Z, Hu W, Zeng S, Wei J, Yang X, Qian L, Zhou S, Sun L, Gong Z, Xu Z (2019) The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer. J Exp Clin Cancer Res 38(1):171–171. https://doi.org/10.1186/s13046-019-1172-5
doi: 10.1186/s13046-019-1172-5
pubmed: 31014370
pmcid: 6480893
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582–598. https://doi.org/10.1038/nrc.2016.73
doi: 10.1038/nrc.2016.73
Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JAM, Tesselaar K, Koenderman L (2010) In vivo labeling with 2H2O reveals a human neutrophil lifespan of 54 days. Blood 116(4):625–627. https://doi.org/10.1182/blood-2010-01-259028
doi: 10.1182/blood-2010-01-259028
pubmed: 20410504
Selders GS, Fetz AE, Radic MZ, Bowlin GL (2017) An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regen Biomater 4(1):55–68. https://doi.org/10.1093/rb/rbw041
doi: 10.1093/rb/rbw041
pubmed: 28149530
pmcid: 5274707
Mittal S, Brown NJ, Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn 18(3):227–243. https://doi.org/10.1080/14737159.2018.1439382
doi: 10.1080/14737159.2018.1439382
pubmed: 29424261
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16(3):183–194. https://doi.org/10.1016/j.ccr.2009.06.017
doi: 10.1016/j.ccr.2009.06.017
pubmed: 19732719
pmcid: 2754404
Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150–12150. https://doi.org/10.1038/ncomms12150
doi: 10.1038/ncomms12150
pubmed: 27381735
pmcid: 4935811
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506
doi: 10.1038/nri2506
pubmed: 19197294
pmcid: 2828349
Ai L, Mu S, Wang Y, Wang H, Cai L, Li W, Hu Y (2018) Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer 18(1):1220–1220. https://doi.org/10.1186/s12885-018-5086-y
doi: 10.1186/s12885-018-5086-y
pubmed: 30518340
pmcid: 6280417
Park MH, Hong JT (2016) Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 5(2):15. https://doi.org/10.3390/cells5020015
doi: 10.3390/cells5020015
pmcid: 4931664
Taniguchi K, Karin M (2018) NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309–324. https://doi.org/10.1038/nri.2017.142
doi: 10.1038/nri.2017.142
pubmed: 29379212
Liu T, Zhang L, Joo D, Sun S-C (2017) NF-κB signaling in inflammation. Signal Transduct Target Ther 2:17023. https://doi.org/10.1038/sigtrans.2017.23
doi: 10.1038/sigtrans.2017.23
pubmed: 29158945
pmcid: 5661633
Zaidi MR (2019) The interferon-gamma paradox in cancer. J Interferon Cytokine Res 39(1):30–38. https://doi.org/10.1089/jir.2018.0087
doi: 10.1089/jir.2018.0087
pubmed: 30388040
pmcid: 6350411
McGeachy MJ, Cua DJ, Gaffen SL (2019) The IL-17 family of cytokines in health and disease. Immunity 50(4):892–906. https://doi.org/10.1016/j.immuni.2019.03.021
doi: 10.1016/j.immuni.2019.03.021
pubmed: 30995505
pmcid: 6474359
Xia Y, Shen S, Verma IM (2014) NF-κB, an active player in human cancers. Cancer Immunol Res 2(9):823–830. https://doi.org/10.1158/2326-6066.CIR-14-0112
doi: 10.1158/2326-6066.CIR-14-0112
pubmed: 4155602
pmcid: 4155602
Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H, Hohensinner P, Basílio J, Petzelbauer P, Assinger A, Schmid JA (2019) Cell type-specific roles of nf-κb linking inflammation and thrombosis. Front Immunol 10:85–85. https://doi.org/10.3389/fimmu.2019.00085
doi: 10.3389/fimmu.2019.00085
pubmed: 30778349
pmcid: 6369217
Qin J-J, Yan L, Zhang J, Zhang W-D (2019) STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res 38(1):195–195. https://doi.org/10.1186/s13046-019-1206-z
doi: 10.1186/s13046-019-1206-z
pubmed: 31088482
pmcid: 6518732
Kim B-H, Yi EH, Ye S-K (2016) Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharmacal Res 39(8):1085–1099. https://doi.org/10.1007/s12272-016-0795-8
doi: 10.1007/s12272-016-0795-8
Lee H, Jeong AJ, Ye S-K (2019) Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep 52(7):415–423. https://doi.org/10.5483/BMBRep.2019.52.7.152
doi: 10.5483/BMBRep.2019.52.7.152
pubmed: 31186087
pmcid: 6675244
Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, Jadidi-Niaragh F (2018) The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 108:1415–1424. https://doi.org/10.1016/j.biopha.2018.09.177
doi: 10.1016/j.biopha.2018.09.177
pubmed: 30372844
Heo T-H, Wahler J, Suh N (2016) Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget 7(13):15460–15473. https://doi.org/10.18632/oncotarget.7102
doi: 10.18632/oncotarget.7102
pubmed: 26840088
pmcid: 4941253
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N, Taketomi A (2017) Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci 108(10):1947–1952. https://doi.org/10.1111/cas.13332
doi: 10.1111/cas.13332
pubmed: 28749573
pmcid: 5623748
Mitani H, Katayama N, Araki H, Ohishi K, Kobayashi K, Suzuki H, Nishii K, Masuya M, Yasukawa K, Minami N, Shiku H (2000) Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. Br J Haematol 109(2):288–295. https://doi.org/10.1046/j.1365-2141.2000.02020.x
doi: 10.1046/j.1365-2141.2000.02020.x
pubmed: 10848814
Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA, Laoui D (2016) M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res 76(1):35. https://doi.org/10.1158/0008-5472.CAN-15-0869
doi: 10.1158/0008-5472.CAN-15-0869
pubmed: 26573801
Lippitz BE, Harris RA (2016) Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology 5(5):e1093722–e1093722. https://doi.org/10.1080/2162402X.2015.1093722
doi: 10.1080/2162402X.2015.1093722
pubmed: 27467926
pmcid: 4910721
Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D’Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H (2015) SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene 34(6):671–680. https://doi.org/10.1038/onc.2014.4
doi: 10.1038/onc.2014.4
pubmed: 24531711
Johnson DE, O’Keefe RA, Grandis JR (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234–248. https://doi.org/10.1038/nrclinonc.2018.8
doi: 10.1038/nrclinonc.2018.8
pubmed: 5858971
pmcid: 5858971
Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang J-J, Kamimura D, Ogura H, Hirano T, Murakami M (2014) Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74(1):8. https://doi.org/10.1158/0008-5472.CAN-13-2322
doi: 10.1158/0008-5472.CAN-13-2322
pubmed: 24362915
Do HTT, Lee CH, Cho J (2020) Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel) 12(2):287. https://doi.org/10.3390/cancers12020287
doi: 10.3390/cancers12020287
Moore BB, Kunkel SL (2019) Attracting attention: discovery of IL-8/CXCL8 and the birth of the chemokine field. J Immunol 202(1):3–4. https://doi.org/10.4049/jimmunol.1801485
doi: 10.4049/jimmunol.1801485
pubmed: 30587567
pmcid: 6559818
Kreckel J, Anany MA, Siegmund D, Wajant H (2019) TRAF2 Controls death receptor-induced caspase-8 processing and facilitates proinflammatory signaling. Front Immunol 10:2024–2024. https://doi.org/10.3389/fimmu.2019.02024
doi: 10.3389/fimmu.2019.02024
pubmed: 31555268
pmcid: 6727177
Derakhshan A, Chen Z, Van Waes C (2017) Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin Cancer Res 23(6):1379–1387. https://doi.org/10.1158/1078-0432.CCR-16-2172
doi: 10.1158/1078-0432.CCR-16-2172
pubmed: 28039268
Oh Y-T, Yue P, Sun S-Y (2017) DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion. Cell Commun Signal 15(1):18–18. https://doi.org/10.1186/s12964-017-0174-1
doi: 10.1186/s12964-017-0174-1
pubmed: 28482915
pmcid: 5422905
Zhang L, Blackwell K, Workman LM, Gibson-Corley KN, Olivier AK, Bishop GA, Habelhah H (2016) TRAF2 exerts opposing effects on basal and TNFα-induced activation of the classic IKK complex in hematopoietic cells in mice. J Cell Sci 129(7):1455–1467. https://doi.org/10.1242/jcs.180554
doi: 10.1242/jcs.180554
pubmed: 26872784
pmcid: 4852721
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I (2020) The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol 43(1):1–18. https://doi.org/10.1007/s13402-019-00489-1
doi: 10.1007/s13402-019-00489-1
Chew CL, Conos SA, Unal B, Tergaonkar V (2018) Noncoding RNAs: master regulators of inflammatory signaling. Trends Mol Med 24(1):66–84. https://doi.org/10.1016/j.molmed.2017.11.003
doi: 10.1016/j.molmed.2017.11.003
pubmed: 29246760
Klinge CM (2018) Non-coding RNAs in breast cancer: intracellular and intercellular communication. Noncoding RNA 4(4):40. https://doi.org/10.3390/ncrna4040040
doi: 10.3390/ncrna4040040
pmcid: 6316884
Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, Norollahi SE, Samadani AA (2020) An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci 240:117077. https://doi.org/10.1016/j.lfs.2019.117077
doi: 10.1016/j.lfs.2019.117077
pubmed: 31751586
Feng Y-H, Tsao C-J (2016) Emerging role of microRNA-21 in cancer. Biomed Rep 5(4):395–402. https://doi.org/10.3892/br.2016.747
doi: 10.3892/br.2016.747
pubmed: 27699004
pmcid: 5038362
Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B, Richardson AL, Frank DA (2014) STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. https://doi.org/10.1126/scisignal.2004497
doi: 10.1126/scisignal.2004497
pubmed: 24473196
pmcid: 4233120
Sever R, Brugge JS (2015) Signal transduction in cancer. Cold Spring Harb Perspect Med 5(4):a006098. https://doi.org/10.1101/cshperspect.a006098
doi: 10.1101/cshperspect.a006098
pubmed: 25833940
pmcid: 4382731
Fan Y, Mao R, Yang J (2013) NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4(3):176–185. https://doi.org/10.1007/s13238-013-2084-3
doi: 10.1007/s13238-013-2084-3
pubmed: 23483479
pmcid: 4875500
Kumari S, Badana AK, Malla GMM (2018) R., 2018 reactive oxygen species: a key constituent in cancer survival. Biomark Insights. https://doi.org/10.1177/1177271918755391
doi: 10.1177/1177271918755391
pubmed: 29449774
pmcid: 5808965
Banerjee K, Resat H (2016) Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 138(11):2570–2578. https://doi.org/10.1002/ijc.29923
doi: 10.1002/ijc.29923
pubmed: 26559373
Rathore R, McCallum JE, Varghese E, Florea A-M, Büsselberg D (2017) Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 22(7):898–919. https://doi.org/10.1007/s10495-017-1375-1
doi: 10.1007/s10495-017-1375-1
pubmed: 28424988
pmcid: 5486846
Cai X, Cao C, Li J, Chen F, Zhang S, Liu B, Zhang W, Zhang X, Ye L (2017) Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1. Oncotarget 8(35):58338–58352. https://doi.org/10.18632/oncotarget.16873
doi: 10.18632/oncotarget.16873
pubmed: 28938560
pmcid: 5601656
Mirzaei SA, Dinmohammadi F, Alizadeh A, Elahian F (2019) Inflammatory pathway interactions and cancer multidrug resistance regulation. Life Sci 235:116825. https://doi.org/10.1016/j.lfs.2019.116825
doi: 10.1016/j.lfs.2019.116825
pubmed: 31494169
Guan X (2015) Cancer metastases: challenges and opportunities. Acta Pharm Sin B 5(5):402–418. https://doi.org/10.1016/j.apsb.2015.07.005
doi: 10.1016/j.apsb.2015.07.005
pubmed: 26579471
pmcid: 4629446
Méndez-García LA, Nava-Castro KE, Ochoa-Mercado TdL, Palacios-Arreola MI, Ruiz-Manzano RA, Segovia-Mendoza M, Solleiro-Villavicencio H, Cázarez-Martínez C, Morales-Montor J (2018) Breast cancer metastasis: are cytokines important players during its development and progression? J Interferon Cytokine Res 39(1):39–55. https://doi.org/10.1089/jir.2018.0024
doi: 10.1089/jir.2018.0024
pubmed: 30321090
Welch DR, Hurst DR (2019) Defining the Hallmarks of Metastasis. Cancer Res 79(12):3011. https://doi.org/10.1158/0008-5472.CAN-19-0458
doi: 10.1158/0008-5472.CAN-19-0458
pubmed: 31053634
pmcid: 6571042
Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC (2016) Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 18(1):84–84. https://doi.org/10.1186/s13058-016-0740-2
doi: 10.1186/s13058-016-0740-2
pubmed: 27515302
pmcid: 4982339
Vinocha A, Grover R, Deepak R (2018) Clinical significance of interleukin-6 in diagnosis of lung, oral, esophageal, and gall bladder carcinomas. J Cancer Res Ther 14(10):758–760. https://doi.org/10.4103/0973-1482.183217
doi: 10.4103/0973-1482.183217
Babic A, Schnure N, Neupane NP, Zaman MM, Rifai N, Welch MW, Brais LK, Rubinson DA, Morales-Oyarvide V, Yuan C, Zhang S, Poole EM, Wolpin BM, Kulke MH, Barbie DA, Wong K, Fuchs CS, Ng K (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9(4):145–145. https://doi.org/10.1038/s41424-018-0008-5
doi: 10.1038/s41424-018-0008-5
pubmed: 29691365
pmcid: 5915593
Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol 10(5):593–619. https://doi.org/10.1586/1744666X.2014.894886
doi: 10.1586/1744666X.2014.894886
pubmed: 24678812
Zhang X, Xiang J (2019) Remodeling the microenvironment before occurrence and metastasis of cancer. Int J Biol Sci 15(1):105–113. https://doi.org/10.7150/ijbs.28669
doi: 10.7150/ijbs.28669
pubmed: 30662351
pmcid: 6329933
Giussani M, Merlino G, Cappelletti V, Tagliabue E, Daidone MG (2015) Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression. Semin Cancer Biol 35:3–10. https://doi.org/10.1016/j.semcancer.2015.09.012
doi: 10.1016/j.semcancer.2015.09.012
pubmed: 26416466
Pires BRB, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Díaz JA, Maia AM, Corrêa S, Abdelhay ESFW (2017) NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE 12(1):e0169622–e0169622. https://doi.org/10.1371/journal.pone.0169622
doi: 10.1371/journal.pone.0169622
pubmed: 28107418
pmcid: 5249109
Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA, Almazyadi HAM, Kallmeyer K, Dandara C, Pepper MS, Parker MI, Dzobo K (2017) The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci 18(7):1586. https://doi.org/10.3390/ijms18071586
doi: 10.3390/ijms18071586
pmcid: 5536073
Correia AL, Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15(1–2):39–49. https://doi.org/10.1016/j.drup.2012.01.006
doi: 10.1016/j.drup.2012.01.006
pubmed: 22335920
pmcid: 3658318
Wu T, Dai Y (2017) Tumor microenvironment and therapeutic response. Cancer Lett 387:61–68. https://doi.org/10.1016/j.canlet.2016.01.043
doi: 10.1016/j.canlet.2016.01.043
Sun Y, Zhu D, Chen F, Qian M, Wei H, Chen W, Xu J (2016) SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene 35(33):4321–4334. https://doi.org/10.1038/onc.2015.494
doi: 10.1038/onc.2015.494
pubmed: 26751775
pmcid: 4994019
Yoshida GJ, Azuma A, Miura Y, Orimo A (2019) Activated fibroblast program orchestrates tumor initiation and progression; molecular mechanisms and the associated therapeutic strategies. Int J Mol Sci 20(9):2256. https://doi.org/10.3390/ijms20092256
doi: 10.3390/ijms20092256
pmcid: 6539414
Deng YW, Hao WJ, Li YW, Li YX, Zhao BC, Lu D (2018) Hsa-miRNA-143-3p reverses multidrug resistance of triple-negative breast cancer by inhibiting the expression of its target protein cytokine-induced apoptosis inhibitor 1 in vivo. J Breast Cancer 21(3):251–258. https://doi.org/10.4048/jbc.2018.21.e40
doi: 10.4048/jbc.2018.21.e40
pubmed: 30275853
pmcid: 6158160
Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 3:120–120. https://doi.org/10.3389/fonc.2013.00120
doi: 10.3389/fonc.2013.00120
pubmed: 23720710
pmcid: 3655421
Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 370(1):153–164. https://doi.org/10.1016/j.canlet.2015.10.010
doi: 10.1016/j.canlet.2015.10.010
pubmed: 26499806
Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao Z, Fan M, Yang CH, Shao Z-M, Pfeffer LM, Wu J, Wu Z-H (2016) Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35(10):1302–1313. https://doi.org/10.1038/onc.2015.189
doi: 10.1038/onc.2015.189
pubmed: 26028030
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410. https://doi.org/10.1038/nrc1093
doi: 10.1038/nrc1093
pubmed: 12778130
Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer E-F, Fehm T, Müller V (2018) The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Res Treat 172(1):93–104. https://doi.org/10.1007/s10549-018-4882-z
doi: 10.1007/s10549-018-4882-z
pubmed: 30003393
Lee P, Chandel NS, Simon MC (2020) Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol 21(5):268–283. https://doi.org/10.1038/s41580-020-0227-y
doi: 10.1038/s41580-020-0227-y
pubmed: 32144406
pmcid: 32144406
Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, Holzer R, Jorcyk C (2019) Co-expression of VEGF and IL-6 family cytokines is associated with decreased survival in HER2 negative breast cancer patients: subtype-specific IL-6 family cytokine-mediated VEGF secretion. Transl Oncol 12(2):245–255. https://doi.org/10.1016/j.tranon.2018.10.004
doi: 10.1016/j.tranon.2018.10.004
pubmed: 30439625
Allahverdiyev AM, Parlar E, Dinparvar S, Bagirova M, Abamor EŞ (2018) Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects. Artif Cells Nanomed Biotechnol 46(sup3):S755–S762. https://doi.org/10.1080/21691401.2018.1511573
doi: 10.1080/21691401.2018.1511573
pubmed: 30260234
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33(9):941–951. https://doi.org/10.1038/nbt.3330
doi: 10.1038/nbt.3330
pubmed: 26348965
pmcid: 4978509
Liu R, Hu C, Yang Y, Zhang J, Gao H (2019) Theranostic nanoparticles with tumor-specific enzyme-triggered size reduction and drug release to perform photothermal therapy for breast cancer treatment. Acta Pharm Sin B 9(2):410–420. https://doi.org/10.1016/j.apsb.2018.09.001
doi: 10.1016/j.apsb.2018.09.001
pubmed: 30976492
Gileva A, Sarychev G, Kondrya U, Mironova M, Sapach A, Selina O, Budanova U, Burov S, Sebyakin Y, Markvicheva E (2019) Lipoamino acid-based cerasomes for doxorubicin delivery: Preparation and in vitro evaluation. Mater Sci Eng C 100:724–734. https://doi.org/10.1016/j.msec.2019.02.111
doi: 10.1016/j.msec.2019.02.111
Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71(8):1185–1198. https://doi.org/10.1111/jphp.13098
doi: 10.1111/jphp.13098
pubmed: 31049986
Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D (2017) Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 67(3):194–232. https://doi.org/10.3322/caac.21397
doi: 10.3322/caac.21397
pubmed: 28436999
pmcid: 5892208
Martins D, Schmitt F (2018) Microenvironment in breast tumorigenesis: Friend or foe? Histol Histopathol 34:18021. https://doi.org/10.14670/HH-18-021
doi: 10.14670/HH-18-021
Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR (2019) Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol 7:4–4. https://doi.org/10.3389/fcell.2019.00004
doi: 10.3389/fcell.2019.00004
pubmed: 30761299
pmcid: 6362613
Thakkar S, Sharma D, Kalia K, Tekade RK (2020) Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater 101:43–68. https://doi.org/10.1016/j.actbio.2019.09.009
doi: 10.1016/j.actbio.2019.09.009
pubmed: 31518706
Wang Z, Li X, Wang D, Zou Y, Qu X, He C, Deng Y, Jin Y, Zhou Y, Zhou Y, Liu Y (2017) Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles. Acta Biomater 62:144–156. https://doi.org/10.1016/j.actbio.2017.08.027
doi: 10.1016/j.actbio.2017.08.027
pubmed: 28842335
Zheng G, Zheng M, Yang B, Fu H, Li Y (2019) Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother 116:109006. https://doi.org/10.1016/j.biopha.2019.109006
doi: 10.1016/j.biopha.2019.109006
pubmed: 31152925
Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z (2016) Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 85:152–167. https://doi.org/10.1016/j.biomaterials.2016.01.061
doi: 10.1016/j.biomaterials.2016.01.061
pubmed: 26871891
Tang S, Meng Q, Sun H, Su J, Yin Q, Zhang Z, Yu H, Chen L, Gu W, Li Y (2017) Dual pH-sensitive micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer. Biomaterials 114:44–53. https://doi.org/10.1016/j.biomaterials.2016.06.005
doi: 10.1016/j.biomaterials.2016.06.005
pubmed: 27842234
Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I (2019) Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci 20(24):6140. https://doi.org/10.3390/ijms20246140
doi: 10.3390/ijms20246140
pmcid: 6941045
Li Y, Lu A, Long M, Cui L, Chen Z, Zhu L (2019) Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts. Acta Biomater 83:334–348. https://doi.org/10.1016/j.actbio.2018.10.029
doi: 10.1016/j.actbio.2018.10.029
pubmed: 30366135
Zhang R, Li Y, Zhang M, Tang Q, Zhang X (2016) Hypoxia-responsive drug–drug conjugated nanoparticles for breast cancer synergistic therapy. RSC Adv 6(36):30268–30276. https://doi.org/10.1039/C6RA01560C
doi: 10.1039/C6RA01560C
Li T, Dong H, Zhang C, Mo R (2018) Cell-based drug delivery systems for biomedical applications. Nano Res 11(10):5240–5257. https://doi.org/10.1007/s12274-018-2179-5
doi: 10.1007/s12274-018-2179-5
Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN (2018) Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Transl Med 7(9):651–663. https://doi.org/10.1002/sctm.18-0024
doi: 10.1002/sctm.18-0024
pubmed: 30070053
pmcid: 6127224
Pi F, Binzel DW, Lee TJ, Li Z, Sun M, Rychahou P, Li H, Haque F, Wang S, Croce CM, Guo B, Evers BM, Guo P (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13(1):82–89. https://doi.org/10.1038/s41565-017-0012-z
doi: 10.1038/s41565-017-0012-z
pubmed: 29230043
Zargar SM, Hafshejani DK, Eskandarinia A, Rafienia M, Kharazi AZ (2019) A review of controlled drug delivery systems based on cells and cell membranes. J Med Signals Sens 9(3):181–189. https://doi.org/10.4103/jmss.JMSS_53_18
doi: 10.4103/jmss.JMSS_53_18
pubmed: 31544058
pmcid: 6743242
Huang Y, Gao X, Chen J (2018) Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B 8(1):4–13. https://doi.org/10.1016/j.apsb.2017.12.001
doi: 10.1016/j.apsb.2017.12.001
pubmed: 29872618
pmcid: 5985693
Sun Y, Su J, Liu G, Chen J, Zhang X, Zhang R, Jiang M, Qiu M (2017) Advances of blood cell-based drug delivery systems. Eur J Pharm Sci 96:115–128. https://doi.org/10.1016/j.ejps.2016.07.021
doi: 10.1016/j.ejps.2016.07.021
pubmed: 27496050
Cao H, Dan Z, He X, Zhang Z, Yu H, Yin Q, Li Y (2016) Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10(8):7738–7748. https://doi.org/10.1021/acsnano.6b03148
doi: 10.1021/acsnano.6b03148
pubmed: 27454827
Di D, Chen L, Wang L, Sun P, Liu Y, Xu Z, Ju J (2016) Downregulation of human intercellular adhesion molecule-1 attenuates the metastatic ability in human breast cancer cell lines. Oncol Rep 35(3):1541–1548. https://doi.org/10.3892/or.2016.4543
doi: 10.3892/or.2016.4543
pubmed: 26751847
Kang T, Zhu Q, Wei D, Feng J, Yao J, Jiang T, Song Q, Wei X, Chen H, Gao X, Chen J (2017) Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 11(2):1397–1411. https://doi.org/10.1021/acsnano.6b06477
doi: 10.1021/acsnano.6b06477
pubmed: 28075552
Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L, Qiang L, Gao S, Gao Y (2017) Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release 266:272–286. https://doi.org/10.1016/j.jconrel.2017.09.042
doi: 10.1016/j.jconrel.2017.09.042
pubmed: 28987884
Zhang Q, Dehaini D, Zhang Y, Zhou J, Chen X, Zhang L, Fang RH, Gao W, Zhang L (2018) Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat Nanotechnol 13(12):1182–1190. https://doi.org/10.1038/s41565-018-0254-4
doi: 10.1038/s41565-018-0254-4
pubmed: 30177807
Wu D, Si M, Xue H-Y, Wong H-L (2017) Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomed 12:5879–5892. https://doi.org/10.2147/IJN.S123437
doi: 10.2147/IJN.S123437
Zhang X, Wu W (2014) Ligand-mediated active targeting for enhanced oral absorption. Drug Discov Today 19(7):898–904. https://doi.org/10.1016/j.drudis.2014.03.001
doi: 10.1016/j.drudis.2014.03.001
pubmed: 24631680
Saleh T, Soudi T, Shojaosadati SA (2019) Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells. Int J Biol Macromol 130:109–116. https://doi.org/10.1016/j.ijbiomac.2019.02.129
doi: 10.1016/j.ijbiomac.2019.02.129
pubmed: 30802519
Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V (2015) Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res 17(1):113–113. https://doi.org/10.1186/s13058-015-0624-x
doi: 10.1186/s13058-015-0624-x
pubmed: 26285572
pmcid: 4541732
Houdaihed L, Evans JC, Allen C (2019) In vivo evaluation of dual-targeted nanoparticles encapsulating paclitaxel and everolimus. Cancers (Basel) 11(6):752. https://doi.org/10.3390/cancers11060752
doi: 10.3390/cancers11060752
Miller-Kleinhenz JM, Bozeman EN, Yang L (2015) Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. WIREs Nanomed Nanobiotechnol 7(6):797–816. https://doi.org/10.1002/wnan.1343
doi: 10.1002/wnan.1343
Cai Z, Chattopadhyay N, Yang K, Kwon YL, Yook S, Pignol J-P, Reilly RM (2016) 111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection. Nucl Med Biol 43(12):818–826. https://doi.org/10.1016/j.nucmedbio.2016.08.009
doi: 10.1016/j.nucmedbio.2016.08.009
pubmed: 27788375
Chen C, Zhao S, Karnad A, Freeman JW (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11(1):64. https://doi.org/10.1186/s13045-018-0605-5
doi: 10.1186/s13045-018-0605-5
pubmed: 29747682
pmcid: 29747682
Arpicco S, De Rosa G, Fattal E (2013) Lipid-based nanovectors for targeting of CD44-overexpressing tumor cells. J Drug Deliv 2013:860780–860780. https://doi.org/10.1155/2013/860780
doi: 10.1155/2013/860780
pubmed: 23533773
pmcid: 3606785
Carton F, Chevalier Y, Nicoletti L, Tarnowska M, Stella B, Arpicco S, Malatesta M, Jordheim LP, Briançon S, Lollo G (2019) Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery. Int J Pharm 568:118526. https://doi.org/10.1016/j.ijpharm.2019.118526
doi: 10.1016/j.ijpharm.2019.118526
pubmed: 31323370
Gupta B, Poudel BK, Ruttala HB, Regmi S, Pathak S, Gautam M, Jin SG, Jeong J-H, Choi H-G, Ku SK, Yong CS, Kim JO (2018) Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin. Acta Biomater 80:364–377. https://doi.org/10.1016/j.actbio.2018.09.006
doi: 10.1016/j.actbio.2018.09.006
pubmed: 30201431
Nguyen VD, Min H-K, Kim C-S, Han J, Park J-O, Choi E (2019) Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Colloids Surf B 173:539–548. https://doi.org/10.1016/j.colsurfb.2018.10.013
doi: 10.1016/j.colsurfb.2018.10.013
Bhanumathi R, Manivannan M, Thangaraj R, Kannan S (2018) Drug-carrying capacity and anticancer effect of the folic acid- and berberine-loaded silver nanomaterial to regulate the AKT-ERK pathway in breast cancer. ACS Omega 3(7):8317–8328. https://doi.org/10.1021/acsomega.7b01347
doi: 10.1021/acsomega.7b01347
pubmed: 30087941
pmcid: 6072244
Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, Yong E-L, Xu HE, Melcher K (2013) Structural basis for molecular recognition of folic acid by folate receptors. Nature 500(7463):486–489. https://doi.org/10.1038/nature12327
doi: 10.1038/nature12327
pubmed: 23851396
pmcid: 5797940
Nieberler M, Reuning U, Reichart F, Notni J, Wester H-J, Schwaiger M, Weinmüller M, Räder A, Steiger K, Kessler H (2017) Exploring the role of RGD-recognizing integrins in cancer. Cancers (Basel) 9(9):116. https://doi.org/10.3390/cancers9090116
doi: 10.3390/cancers9090116
Zhang J, Zhang P, Zou Q, Li X, Fu J, Luo Y, Liang X, Jin Y (2018) Co-delivery of gemcitabine and paclitaxel in cRGD-modified long circulating nanoparticles with asymmetric lipid layers for breast cancer treatment. Molecules 23(11):2906. https://doi.org/10.3390/molecules23112906
doi: 10.3390/molecules23112906
pmcid: 6278289
He X, Alves CS, Oliveira N, Rodrigues J, Zhu J, Bányai I, Tomás H, Shi X (2015) RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. Colloids Surf B 125:82–89. https://doi.org/10.1016/j.colsurfb.2014.11.004
doi: 10.1016/j.colsurfb.2014.11.004
Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X (2019) Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat Nanotechnol 14(4):388–397. https://doi.org/10.1038/s41565-019-0381-6
doi: 10.1038/s41565-019-0381-6
pubmed: 30804480
pmcid: 6449187
Pawar A, Prabhu P (2019) Nanosoldiers: a promising strategy to combat triple negative breast cancer. Biomed Pharmacother 110:319–341. https://doi.org/10.1016/j.biopha.2018.11.122
doi: 10.1016/j.biopha.2018.11.122
pubmed: 30529766
Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X (2017) Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 8(1):1913–1924. https://doi.org/10.18632/oncotarget.12284
doi: 10.18632/oncotarget.12284
pubmed: 27765921
Colombo M, Rizzuto MA, Pandolfi L, Pacini C, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S (2018) Half-Chain cetuximab nanoconjugates allow multitarget therapy of triple negative breast cancer. Bioconjug Chem. https://doi.org/10.1021/acs.bioconjchem.8b00667
doi: 10.1021/acs.bioconjchem.8b00667
pubmed: 30350574
Hossein-Nejad-Ariani H, Althagafi E, Kaur K (2019) Small peptide ligands for targeting EGFR in triple negative breast cancer cells. Sci Rep 9(1):2723–2723. https://doi.org/10.1038/s41598-019-38574-y
doi: 10.1038/s41598-019-38574-y
pubmed: 30804365
pmcid: 6389950
Deshmukh SK, Srivastava SK, Poosarla T, Dyess DL, Holliday NP, Singh AP, Singh S (2019) Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med 7(20):593–593. https://doi.org/10.21037/atm.2019.09.68
doi: 10.21037/atm.2019.09.68
pubmed: 31807574
pmcid: 6861749